Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis
Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis
复制标题
DOI：
10.1007/s10072-012-0974-4
复制
发表时间：
2013-02-01
影响因子：
3.3
通讯作者：
Montella, Andrea
中科院分区：
文献类型：
--
作者：
Madeddu, Roberto;Farace, Cristiano;Montella, Andrea
轴突细胞骨架是一个精细的组织系统，对维持轴突的完整性至关重要。轴突变性与多发性硬化（MS）的持续残疾的发病机制有关。本研究的目的是评估MS患者脑脊液（CSF）中细胞骨架蛋白（如神经丝轻蛋白（NFL）、胶质细胞酸性蛋白（GFAP）和β-微管蛋白（β-Tub）亚型II和III）的水平及其与MS临床指标的相关性。在51名患者中测定了CSF细胞骨架蛋白水平：33名MS患者和18名其他神经系统疾病（OND）患者。NFL、GFAP和β-Tub II蛋白在MS中显著高于OND组（p < 0.0001）; β-Tub III在MS和OND组之间没有显著差异（p > 0.05）。有趣的是，β-Tub III和NFL的水平在进行性MS形式中高于缓解性MS形式;相反，在缓解性MS形式中发现更高水平的β-Tub II和GFAP。然而，除β-Tub III外，所有蛋白质都倾向于降低其CSF水平，同时增加残疾（EDSS）评分。总体而言，我们的研究结果可能表明β-Tub II作为MS诊断的潜在候选者，β-Tub III作为MS的可能预后生物标志物。因此，进一步的分析是合理和可取的。
The axonal cytoskeleton is a finely organized system, essential for maintaining the integrity of the axon. Axonal degeneration is implicated in the pathogenesis of unremitting disability of multiple sclerosis (MS). Purpose of this study is to evaluate levels of cytoskeletal proteins such as neurofilament light protein (NFL), glial fibrillary acidic protein (GFAP), and beta-tubulin (beta-Tub) isoforms II and III in the cerebrospinal fluid (CSF) of MS patients and their correlation with MS clinical indices. CSF levels of cytoskeletal proteins were determined in 51 patients: 33 with MS and 18 with other neurological diseases (OND). NFL, GFAP and beta-Tub II proteins were significantly higher (p < 0.0001) in MS than in OND group; no significant difference (p > 0.05) was found between MS and OND with regard to beta-Tub III. Interestingly, levels of beta-Tub III and NFL were higher in progressive than in remitting MS forms; on the contrary, higher levels of beta-Tub II and GFAP were found in remitting MS forms. However, with the exception of beta-Tub III, all proteins tend to decrease their CSF levels concomitantly with the increasing disability (EDSS) score. Overall, our results might indicate beta-Tub II as a potential candidate for diagnostic and beta-Tub III as a possible prognostic biomarker of MS. Therefore, further analyses are legitimated and desirable.